NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC
NKT2152 demonstrates anti-tumor activity in heavily pretreated advanced clear cell RCC
Status of anti BCMA therapy in myeloma
The promise of CAR T cell therapy for multiple myeloma
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Durable responses in aRCC, how do we optimise treatment?
Bladder cancer updates from the first half of 2024
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Biomarkers, predictive and prognostic factors of resistance to immunotherapy
GIST tumours and soft tissue sarcomas